Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 12/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495550 | 0.80 | HTR3E (0.50) | KDM4EALDH1A1LMNAHPGDHTR3E | |
| SCHEMBL3496156 | 0.76 | HTR3E (0.52) | KDM4EALDH1A1LMNAHPGDHTR3E | |
| SCHEMBL3495071 | 0.68 | MAPK8 (0.49) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL3496299 | 0.68 | MAPK8 (0.49) | ALDH1A1LMNAHTR3EHTR3BHTR3A | |
| SCHEMBL3495173 | 0.68 | MAPK8 (0.47) | KDM4EALDH1A1LMNAHPGDHTR3E | |
| SCHEMBL3496028 | 0.67 | BRD4 (0.52) | BRD4MAPK8 | |
| SCHEMBL3496822 | 0.67 | MAPK8 (0.46) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL13340307 | 0.66 | MAPK8 (0.45) | KDM4EALDH1A1LMNAHPGDHTR3E | |
| SCHEMBL17895250 | 0.65 | MAPK8 (0.66) | BRD4MAPK8 | |
| SCHEMBL14044179 | 0.65 | MAPK8 (0.48) | KDM4EALDH1A1LMNAHPGDHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513250-B2 | Imidazolo-heteroaryl derivatives with antibacterial properties | LABORATOIRE BIODIM (FR) | 2013-08-20 | — | — | US | disclosed |
| US-8513250-B2 | Imidazolo-heteroaryl derivatives with antibacterial properties | LABORATOIRE BIODIM (FR) | 2013-08-20 | — | — | US | disclosed |
| US-20100130489-A1 | IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2010-05-27 | — | — | US | disclosed |
| US-20100130489-A1 | IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2010-05-27 | — | — | US | disclosed |
| WO-2008117225-A2 | NEW IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2008-10-02 | — | — | WO | disclosed |
| EP-1972629-A1 | New imidazolo-heteroaryl derivatives with antibacterial properties | Mutabilis SA (FR) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130489-A1 | IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | DLAT, DLST, DNTT | KDM4E 1703/4885ALDH1A1 1002/4885LMNA 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.